No, abiraterone plus bicalutamide is not appropriate for metastatic prostate cancer
The combination of abiraterone and bicalutamide should not be used together for metastatic prostate cancer. This combination has not been studied and is not supported by any guideline or evidence.
The Correct Treatment Approach
For Metastatic Castration-Sensitive (Hormone-Naïve) Prostate Cancer
Abiraterone should be combined with ADT (androgen deprivation therapy) plus prednisone/prednisolone—NOT with bicalutamide 1, 2, 1.
The FDA-approved and guideline-recommended regimen is:
- Abiraterone 1,000 mg once daily
- Plus prednisone 5 mg twice daily (or prednisolone)
- Plus ADT (LHRH agonist, LHRH antagonist, or orchiectomy)
This triple combination is indicated for 3:
- High-risk metastatic hormone-sensitive disease (LATITUDE criteria: ≥2 of Gleason ≥8, ≥3 bone metastases, visceral metastases) 1, 2
- Lower-risk metastatic disease may also be offered this combination 2
Why Not Bicalutamide with Abiraterone?
Bicalutamide is a first-generation antiandrogen that serves as an alternative to abiraterone, not a complement to it 4. The evidence clearly shows:
- Abiraterone is superior to bicalutamide when each is combined with ADT 5, 6, 7, 8
- Studies comparing these agents show abiraterone significantly prolongs time to castration resistance and improves survival outcomes compared to bicalutamide plus ADT 6, 7
- Using both together has no evidence base and is not recommended 1, 2, 1
The Standard Treatment Options for Metastatic Disease
For newly diagnosed metastatic castration-sensitive prostate cancer, you have four separate standards of care 2:
- ADT + abiraterone + prednisone
- ADT + enzalutamide
- ADT + apalutamide
- ADT + docetaxel (particularly for high-volume disease)
These cannot be combined with each other or used in any particular sequence without evidence 1, 2.
Common Pitfall to Avoid
The critical error here is thinking that adding bicalutamide to abiraterone provides additional androgen blockade benefit. In reality:
- Abiraterone blocks androgen synthesis (CYP17 inhibitor)
- Bicalutamide blocks the androgen receptor
- However, abiraterone already requires concurrent ADT (which achieves castrate testosterone levels), making bicalutamide redundant and unsupported
- The steroid (prednisone/prednisolone) given with abiraterone is to prevent mineralocorticoid excess, not for additional cancer control 4
For Metastatic Castration-Resistant Prostate Cancer
If the disease has already progressed to castration-resistant state, abiraterone is still used with prednisone plus continued ADT—again, not with bicalutamide 9, 10, 3.
Bottom line: Use abiraterone with ADT and prednisone/prednisolone as a complete regimen. Do not add bicalutamide to this combination.